RESEARCH & DEVELOPMENT
XPose Therapeutics is very excited to receive non-dilutive funding (SBIR Phase I) from the National Cancer Institute of the National Institutes of Health to advance the discovery and development of novel therapeutics targeting DDR in cancer.
Full announcement here.
XPose Therapeutics accepted into Spring 2020 session of Berkeley SkyDeck HotDesk (Incubator) program.
XPose Therapeutics licences hits from Accelero Biostructures for launching focused therapeutics development for DDR target APE1.
XPose Therapeutics ("X-ray Poses" or "XPose") receives support for launch from University of California's QB3.